Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gawish, A; Abdullayev, N; El-Arayedh, S; Röllich, B; Ochel, HJ; Brunner, TB.
Metabolic response after 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases prostate cancer.
Clin Transl Oncol. 2023; 25(4):987-994 Doi: 10.1007/s12094-022-03002-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Brunner Thomas Baptist
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: We used 68Ga PSMA PET/CT in the current investigation to assess the metabolic response and local control of metastasis in patients with oligometastatic prostate cancer receiving SBRT. MATERIALS AND PROCEDURES: We performed a retrospective evaluation of the medical data of all patients with oligometastatic prostate cancer who underwent stereotactic body radiation therapy (SBRT) between 2017 and 2021. Our analysis only included medical records of patients who had SBRT for oligometastatic prostate cancer and had pre and post-SBRT 68Ga PSMA PET/CT images. Patient-related (age), disease-related (Gleason score, location of metastases), and treatment-related (factors and outcomes) data were collected from the medical files. RESULTS: A total of 17 patients (28 lesions) with a median age of 69 years were included in the research. A median follow-up of 16.6 months was used (range 6-36 months). The median follow-up period for 68 Ga PSMA PET/CT was 8 months (the range was 5-24 months). The median pre-treatment PSA level was 1.7 ng/mL (range 0.39-18.3 ng/mL) compared to the post-treatment PSA nadir of 0.05 ng/mL (0.02-4.57). During the follow-up period, local control was 96%, and there was a link between PSMA avidity on PET. In the treated lesions, there were no recurrences. During follow-up, none of the patients experienced toxicities of grade 3 or above. CONCLUSIONS: SBRT is a highly successful and safe way of treating patients with oligometastatic prostate cancer. Additional research is needed to examine 68Ga PSMA PET/CT to assess further for demarcation and follow-up.
Find related publications in this database (using NLM MeSH Indexing): Male - administration & dosage; Humans - administration & dosage; Aged - administration & dosage; Positron Emission Tomography Computed Tomography - methods; Prostate-Specific Antigen - administration & dosage; Radiosurgery - methods; Retrospective Studies - administration & dosage; Prostatic Neoplasms - diagnostic imaging, radiotherapy, pathology
Find related publications in this database (Keywords): SBRT; Prostate cancer; Oligometastatic; PSMA-PET